Table 2 Part 2. Baseline clinical data of controlled study (n = 50)
Variables | Tranexamic acid (n = 24) | Placebo (n = 26) | P value |
|---|---|---|---|
Demographic | |||
Age, years | 66 (63–70) | 67 (62–71) | 0.91 |
Male gender, number (percentage) | 12 (50) | 15 (57) | 0.58 |
Body mass index, kg/m2 | 28 (25.8–30.1) | 28.1 (36.4–29.7) | 0.98 |
Parsonnet score | 13.1 (11.8–15.5) | 17.5 (13.7–21.3) | 0.07 |
Comorbidity | |||
Cardiopathy, number (percentage) | |||
Coronary | 13 (54) | 12 (46) | 0.71 |
Valve | 9 (38) | 10 (39) | 0.68 |
Mixed | 2 (8) | 4 (15) | 0.44 |
Medical treatment | |||
Angiotensin-converting enzyme inhibitors, number (percentage) | 11 (61) | 7 (39) | 0.16 |
Calcium channel blockers, number (percentage) | 6 (60) | 4 (40) | 0.39 |
Preoperative parameters | |||
Platelet count, × 103/mL | 210 (186–234) | 210 (186–239) | 0.68 |
Hemoglobin, g/dL | 14.1 (13.5–14.6) | 13.6 (12.8–14.4) | 0.42 |
International normalized ratio | 1.08 (1.05–1.12) | 1.09 (1.05–1.14) | 0.97 |
D-dimer, ng/mL | 250 (166–333) | 275 (215–325) | 0.34 |
Plasminogen activator inhibitor 1, ng/mL | 34.2 (29–39.5) | 35.2 (29.4–41.1) | 0.95 |
Surgical data | |||
Cardiopulmonary bypass time, minutes | 82 (71–94) | 85 (74–96) | 0.30 |
Aortic clamping time, minutes | 51 (44–58) | 55 (47–62) | 0.35 |
Temperature after cardiopulmonary bypass, degrees Celsius | 35.3 (34.9–35.6) | 35.1 (34.7–35.3) | 0.24 |
Total heparin dose, UI/kg | 430 (400–470) | 420 (400–440) | 0.69 |
Total protamine dose, mg/kg | 2.7 (2.5–3) | 2.7 (2.6–2.9) | 0.72 |
Blood salvage device, mL | 681 (605–756) | 764 (694–833) | 0.12 |